1-硝基-3-(1-叠氮乙基)苯 | 246240-16-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-硝基-3-(1-叠氮乙基)苯
• 英文名称: 1-(1-azidoethyl)-3-nitrobenzene
• 英文别名: 1-Nitro-3-(1-azidoethyl)benzene
• CAS: 246240-16-4
• 化学式: C₈H₈N₄O₂
• 分子量: 192.177
• InChiKey: OJMDFRMRSPQROO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  60.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-硝基-3-(1-叠氮乙基)苯 在 sodium hydroxide 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 生成 1-(3-硝基苯)乙胺
  参考文献：
  名称：

  Methods for inhibiting mrp1

  摘要：

  本发明涉及一种化合物，其化学式为（I），用于抑制抗药性新生物，其中该抗药性部分或全部由MRP1赋予。

  公开号：

  US06369070B1
• 作为产物：
  描述：

  1-(3-硝基苯基)乙醇 在 1-methylimidazolium tetrafluoroborate 、 sodium azide 作用下， 反应 8.0h， 以49%的产率得到1-硝基-3-(1-叠氮乙基)苯
  参考文献：
  名称：

  布朗斯台德酸性离子液体[HMIM] [BF4]作溶剂和催化剂由醇单锅绿色合成叠氮化物

  摘要：

  布朗斯台德酸性离子液体[HMIM] [BF 4 ]已被用作非挥发性，生态友好型溶剂和催化介质，用于由相应的醇一次绿色合成叠氮化物。[HMIM] [BF 4 ]具有比[BMIM] [BF 4 ]和[BMIM] [PF 6 ]高的反应活性，提供的叠氮化物产率高达97％，可以很容易地从反应混合物中分离出来。[HMIM] [BF 4 ]的易回收性使该反应在经济上可行，并可能在实际应用中可行。

  DOI：

  10.1002/jccs.201400046

文献信息

• A mild and efficient method for preparation of azides from alcohols using acidic ionic liquid [H-NMP]HSO4
  作者：Abdol R. Hajipour、Asiyeh Rajaei、Arnold E. Ruoho

  DOI：10.1016/j.tetlet.2008.11.111

  日期：2009.2

  We report here an efficient method for the synthesis and characterization of [H-NMP]HSO4 and its application as an efficient catalyst and solvent for preparation of azides from corresponding alcohols under mild conditions. This processor showed high chemoselectivity for conversion of various alcohols to their corresponding azides.

  我们在这里报告了一种有效的合成和表征[H-NMP] HSO 4的方法，并将其作为在温和条件下由相应的醇制备叠氮化物的有效催化剂和溶剂的应用。该处理器显示出高的化学选择性，可将各种醇转化为其相应的叠氮化物。
• Inhibitors of IMPDH enzyme
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US07087642B2

  公开（公告）日：2006-08-08

  The present invention relates to compounds which inhibit IMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting IMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of IMPDH using the compounds of this invention and related compounds.

  本发明涉及抑制IMPDH的化合物。本发明还涉及包含这些化合物的制药组合物。本发明的化合物和制药组合物特别适用于抑制IMPDH酶活性，因此可以优势地用作IMPDH介导过程的治疗剂。本发明还涉及使用本发明的化合物和相关化合物抑制IMPDH活性的方法。
• Transition-metal-free azide insertion of <i>N</i>-triftosylhydrazones using a non-metallic azide source
  作者：Xueyu Li、Jin-Na Song、Swastik Karmakar、Ying Lu、Ye Lv、Peiqiu Liao、Zhaohong Liu

  DOI：10.1039/d2cc05442f

  日期：——

  Benzylic azides, an important class of active organic synthons, were synthesized in high yields from the easily accessible N-triftosylhydrazones with stable TMSN3 under mild conditions. The reaction features high efficiency and excellent functional group tolerance, as illustrated by gram-scale synthesis and the synthesis of drug-like molecules. Mechanistic studies reveal that azidation occurs at the

  苄基叠氮化物是一类重要的活性有机合成子，在温和条件下从易于获得的具有稳定 TMSN 3的N -triftosylhydrazone 以高产率合成。该反应具有高效和优异的官能团耐受性，如克级合成和类药分子的合成所示。机理研究表明，通过叠氮离子消除 N 2，在缺电子的重氮碳中发生叠氮化。
• Design, synthesis and biological evaluation of novel inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitors
  作者：Torsten Dunkern、Sunil Chavan、Digambar Bankar、Anuja Patil、Pritee Kulkarni、Prashant S. Kharkar、Arati Prabhu、Heike Goebel、Edith Rolser、Waltraud Burckhard-Boer、Premkumar Arumugam、Mahindra T. Makhija

  DOI：10.3109/14756366.2013.793184

  日期：2014.6.1

  This study is based on our attempts to further explore the structure-activity relationship (SAR) of VX-148 (3) in an attempt to identify inosine 5'-mono-phosphate dehydrogenase (IMPDH) inhibitors superior to mycophenolic acid. A five-point pharmacophore developed using structurally diverse, known IMPDH inhibitors guided further design of novel analogs of 3. Several conventional as well as novel medicinal chemistry strategies were tried. The combined structure-and ligand-based approaches culminated in a few analogs with either retained or slightly higher potency. The compounds which retained the potency were also checked for their ability to inhibit human peripheral blood mononuclear cells proliferation. This study illuminates the stringent structural requirements and strict SAR for IMPDH II inhibition.
• INHIBITORS OF IMPDH ENZYME
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1178797B1

  公开（公告）日：2013-02-20